154 related articles for article (PubMed ID: 7533319)
21. Contrast-enhanced ultrasound may aid prostate cancer detection.
Fillon M
J Natl Cancer Inst; 2013 Apr; 105(7):444-6. PubMed ID: 23492350
[No Abstract] [Full Text] [Related]
22. The role of ultrasound in prostate cancer detection in patients with an elevated prostate specific antigen level but no prostatic nodule.
Sanders RC
Md Med J; 1993 Oct; 42(10):1007-11. PubMed ID: 7505045
[TBL] [Abstract][Full Text] [Related]
23. [Comparison between 2 techniques of screening for prostatic carcinoma. Rectal exploration and transrectal ultrasonography vs. prostate specific antigen].
Ciatto S; Bonardi R; Mazzotta A; Lombardi C; Santoni R; Cardini S; Zappa M
Radiol Med; 1994 Oct; 88(4):453-7. PubMed ID: 7527916
[TBL] [Abstract][Full Text] [Related]
24. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).
Roobol MJ; Schröder FH; van Leenders GL; Hessels D; van den Bergh RC; Wolters T; van Leeuwen PJ
Eur Urol; 2010 Dec; 58(6):893-9. PubMed ID: 20933321
[TBL] [Abstract][Full Text] [Related]
25. [The diagnosis of prostatic carcinoma].
Hammerer P; Huland H
Fortschr Med; 1991 Sep; 109(26):512-7. PubMed ID: 1723711
[TBL] [Abstract][Full Text] [Related]
26. [Prostatic specific antigen (PA) in mass screening for prostate cancer].
Ito K; Ohtake N; Hatori M; Mashimo T; Jimbo S; Tomaru Y; Makino T; Yajima H; Imai K; Yamanaka H
Hinyokika Kiyo; 1992 Nov; 38(11):1225-9. PubMed ID: 1283053
[TBL] [Abstract][Full Text] [Related]
27. Determination of prostate volume with transrectal ultrasound for cancer screening. Part I. Comparison with prostate specific antigen assays.
Hricak H; Carroll P
Invest Radiol; 1992 Sep; 27(9):751-3. PubMed ID: 1383174
[No Abstract] [Full Text] [Related]
28. Can we accurately identify men with low risk prostate cancer?
Neal DE
J Urol; 2008 Oct; 180(4):1217-8. PubMed ID: 18707718
[No Abstract] [Full Text] [Related]
29. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.
Thompson IM; Ankerst DP; Etzioni R; Wang T
J Urol; 2008 Oct; 180(4):1219-22. PubMed ID: 18707707
[No Abstract] [Full Text] [Related]
30. Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
Joniau S
Eur Urol; 2008 Feb; 53(2):362. PubMed ID: 17611018
[No Abstract] [Full Text] [Related]
31. Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
Scattoni V
Eur Urol; 2008 Feb; 53(2):361. PubMed ID: 17611014
[No Abstract] [Full Text] [Related]
32. Is preoperative transrectal ultrasonography of value in localised prostatic carcinoma? A blind comparative study between preoperative transrectal ultrasonography and the histopathological radical prostatectomy specimen.
Vijverberg PL; Giessen MC; Kurth KH; Dabhoiwala NF; de Reijke TM; van den Tweel JG
Eur J Surg Oncol; 1992 Oct; 18(5):449-55. PubMed ID: 1426295
[TBL] [Abstract][Full Text] [Related]
33. [Ultrasound-guided transrectal biopsy of the prostate].
Mayayo Dehesa T
Arch Esp Urol; 1993 Dec; 46(10):849-53. PubMed ID: 7511365
[No Abstract] [Full Text] [Related]
34. Prostate cancer: 5. Diagnostic tools for early detection.
Karakiewicz PI; Aprikian AG
CMAJ; 1998 Nov; 159(9):1139-46. PubMed ID: 9835884
[No Abstract] [Full Text] [Related]
35. [The prostate-specific antigen in the early recognition of prostate carcinoma].
Wolff JM; Jakse G
Dtsch Med Wochenschr; 1996 Nov; 121(48):1508-14. PubMed ID: 8983908
[No Abstract] [Full Text] [Related]
36. [Circulating prostatic-specific antigen in benign hypertrophy and localized prostate cancer: can PSA be considered a screening examination for localized cancer?].
Perrin P; Francois O; Maquet JH; Bringeon G; Duteil P; Devonec M
Prog Urol; 1991 Jun; 1(3):419-31. PubMed ID: 1726943
[TBL] [Abstract][Full Text] [Related]
37. [Sonographic diagnosis of prostatic cancer].
Hammerer PG
Radiologe; 1994 Mar; 34(3):116-21. PubMed ID: 7513895
[TBL] [Abstract][Full Text] [Related]
38. [Prostate specific antigen (PSA): impact of a seric marker on the diagnosis and therapeutic management of cancers of the prostate].
Chauvet B; Jacob T; Davin JL; Berger C; Vincent P; Reboul F
Bull Cancer Radiother; 1996; 83(4):334-44. PubMed ID: 9081335
[No Abstract] [Full Text] [Related]
39. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
40. [Pathological basis for elevation of serum prostate specific antigen].
Xia TL; Deng FM; Feng T
Zhonghua Yi Xue Za Zhi; 1994 May; 74(5):306-8, 327. PubMed ID: 7525028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
